文献速递临床试验与 GCP

微创肺表面活性物质治疗与假治疗对早产儿呼吸窘迫综合征死亡或支气管肺发育不良的影响:OPTIMIST-A随机临床试验

Effect of Minimally Invasive Surfactant Therapy vs Sham Treatment on Death or Bronchopulmonary Dysplasia in Preterm Infants With Respiratory Distress Syndrome: The OPTIMIST-A Randomized Clinical Trial.
PubMed 文献 · JAMA · 2021-01-01

这项随机临床试验纳入485例胎龄25至28周、出生6小时内需吸入氧浓度≥0.30的呼吸窘迫综合征早产儿,比较经细导管给予肺表面活性物质(MIST)与假治疗。MIST组死亡或支气管肺发育不良发生率为43.6%,对照组为49.6%,差异未达统计学显著(RD -6.3%,95%CI -14.2%至1.6%;RR 0.87,95%CI 0.74至1.03;P=0.10)。

要点

  • MIST组死亡或生理性BPD复合结局43.6%,对照组49.6%,差异未达统计学显著。
  • 存活至36周矫正胎龄者中,MIST组BPD发生率37.3%,低于对照组45.3%(RD -7.8%,95%CI -14.9%至-0.7%)。
  • 两组36周矫正胎龄前死亡发生率无显著差异(MIST组10.0% vs 对照组7.8%)。

核心结论

  • 在CPAP支持的呼吸窘迫综合征早产儿中,与假治疗相比,MIST未显著降低36周矫正胎龄时死亡或BPD复合结局的发生率。
  • 鉴于95%CI反映的统计不确定性,不能排除具有临床重要性的效应。

研究设计与样本

  • 随机临床试验,纳入485例胎龄25至28周、CPAP支持且出生6小时内需吸入氧浓度≥0.30的早产儿。
  • 试验在全世界33个三级新生儿重症监护病房开展,对临床医生和结局评估者设盲。
  • 入组时间为2011年12月16日至2020年3月26日,随访于2020年12月2日完成。
  • MIST组241例经细导管给予猪肺磷脂α 200 mg/kg,对照组244例接受假治疗,之后两组均继续CPAP除非满足指定插管标准。

主要发现

  • MIST组死亡或BPD 105例(43.6%),对照组121例(49.6%)(RD -6.3%,95%CI -14.2%至1.6%;RR 0.87,95%CI 0.74至1.03;P=0.10)。
  • 36周矫正胎龄前死亡:MIST组24例(10.0%)vs 对照组19例(7.8%)(RD 2.1%,95%CI -3.6%至7.8%;RR 1.27,95%CI 0.63至2.57;P=0.51)。
  • 存活至36周矫正胎龄者中BPD:MIST组81/217例(37.3%)vs 对照组102/225例(45.3%)(RD -7.8%,95%CI -14.9%至-0.7%;RR 0.83,95%CI 0.70至0.98;P=0.03)。
  • 严重不良事件:MIST组10.3%,对照组11.1%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文指出,鉴于95%CI反映的统计不确定性,不能排除具有临床重要性的效应。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: The benefits of surfactant administration via a thin catheter (minimally invasive surfactant therapy [MIST]) in preterm infants with respiratory distress syndrome are uncertain. OBJECTIVE: To examine the effect of selective application of MIST at a low fraction of inspired oxygen threshold on survival without bronchopulmonary dysplasia (BPD). DESIGN, SETTING, AND PARTICIPANTS: Randomized clinical trial including 485 preterm infants with a gestational age of 25 to 28 weeks who were supported with continuous positive airway pressure (CPAP) and required a fraction of inspired oxygen of 0.30 or greater within 6 hours of birth. The trial was conducted at 33 tertiary-level neonatal intensive care units around the world, with blinding of the clinicians and outcome assessors. Enrollment took place between December 16, 2011, and March 26, 2020; follow-up was completed on December 2, 2020. INTERVENTIONS: Infants were randomized to the MIST group (n = 241) and received exogenous surfactant (200 mg/kg of poractant alfa) via a thin catheter or to the control group (n = 244) and received a sham (control) treatment; CPAP was continued thereafter in both groups unless specified intubation criteria were met. MAIN OUTCOMES AND MEASURES: The primary outcome was the composite of death or physiological BPD assessed at 36 weeks' postmenstrual age. The components of the primary outcome (death prior to 36 weeks' postmenstrual age and BPD at 36 weeks' postmenstrual age) also were considered separately. RESULTS: Among the 485 infants randomized (median gestational age, 27.3 weeks; 241 [49.7%] female), all completed follow-up. Death or BPD occurred in 105 infants (43.6%) in the MIST group and 121 (49.6%) in the control group (risk difference [RD], -6.3% [95% CI, -14.2% to 1.6%]; relative risk [RR], 0.87 [95% CI, 0.74 to 1.03]; P = .10). Incidence of death before 36 weeks' postmenstrual age did not differ significantly between groups (24 [10.0%] in MIST vs 19 [7.8%] in control; RD, 2.1% [95% CI, -3.6% to 7.8%]; RR, 1.27 [95% CI, 0.63 to 2.57]; P = .51), but incidence of BPD in survivors to 36 weeks' postmenstrual age was lower in the MIST group (81/217 [37.3%] vs 102/225 [45.3%] in the control group; RD, -7.8% [95% CI, -14.9% to -0.7%]; RR, 0.83 [95% CI, 0.70 to 0.98]; P = .03). Serious adverse events occurred in 10.3% of infants in the MIST group and 11.1% in the control group. CONCLUSIONS AND RELEVANCE: Among preterm infants with respiratory distress syndrome supported with CPAP, minimally invasive surfactant therapy compared with sham (control) treatment did not significantly reduce the incidence of the composite outcome of death or bronchopulmonary dysplasia at 36 weeks' postmenstrual age. However, given the statistical uncertainty reflected in the 95% CI, a clinically important effect cannot be excluded. TRIAL REGISTRATION: anzctr.org.au Identifier: ACTRN12611000916943.

来源:JAMA,查看原文。版权归原作者所有。

引用

  1. Dargaville PA, Kamlin COF, Orsini F, et al. Effect of Minimally Invasive Surfactant Therapy vs Sham Treatment on Death or Bronchopulmonary Dysplasia in Preterm Infants With Respiratory Distress Syndrome: The OPTIMIST-A Randomized Clinical Trial. JAMA. 2021. PMID: 34902013. doi:10.1001/jama.2021.21892

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。